Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Rezpegaldesleukin Formulations in Healthy Participants
NCT05565729Phase 1Completed
- Sponsor
- Nektar Therapeutics
- Start
- Oct 2022
- Primary completion
- Feb 2023
- Modality
- Biologic, rProtein (Recombinant Protein), Polyethylene glycol conjugate
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of rezpegaldesleukin in systemic lupus erythematosus (SLE), atopic dermatitis (AD) and psoriasis (4 arms), sponsored by Nektar Therapeutics. Primary endpoints: Maximum Concentration and Area Under the Concentration Versus Time Curve. Started Oct 2022; status: completed.
02
Drugs
rezpegaldesleukin
03
Conditions
systemic lupus erythematosus (SLE)atopic dermatitis (AD)psoriasis
Beyond the preview
Go deeper on NCT05565729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05565729.